Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

• Status: Active, not recruiting
• Trial end date: 2021-12-31

Summary

This phase II trial studies how well nivolumab and temozolomide work in treating patients with small-cell lung cancer that has come back or does not respond to treatment, or neuroendocrine cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and temozolomide may work better in treating patients with small-cell lung cancer and neuroendocrine cancer.

• Phase: Phase 2

Details

• Lead Sponsor: Dwight Owen
• Collaborators: Bristol-Myers Squibb; National Cancer Institute (NCI)
• Treatments: Antibodies, Monoclonal; Dacarbazine; Nivolumab; Temozolomide